Antibiotics (Apr 2022)

Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic

  • Tommaso Lupia,
  • Ilaria De Benedetto,
  • Giacomo Stroffolini,
  • Stefano Di Bella,
  • Simone Mornese Pinna,
  • Verena Zerbato,
  • Barbara Rizzello,
  • Roberta Bosio,
  • Nour Shbaklo,
  • Silvia Corcione,
  • Francesco Giuseppe De Rosa

DOI
https://doi.org/10.3390/antibiotics11040493
Journal volume & issue
Vol. 11, no. 4
p. 493

Abstract

Read online

Temocillin is an old antibiotic, but given its particular characteristics, it may be a suitable alternative to carbapenems for treating infections due to ESBL-producing Enterobacterales and uncomplicated UTI due to KPC-producers. In this narrative review, the main research question was to summarize current evidence on temocillin and its uses in infectious diseases. A search was run on PubMed using the terms (‘Temocillin’ [Mesh]) AND (‘Infection’ [Mesh]). Current knowledge regarding temocillin in urinary tract infection, blood-stream infections, pneumonia, intra-abdominal infections, central nervous system infections, skin and soft tissues infections, surgical sites infections and osteoarticular Infections were summarized. Temocillin retain a favourable profile on microbiota and risk of Clostridioides difficile infections and could be an option for treating outpatients. Temocillin may be a valuable tool to treat susceptible pathogens and for which a carbapenem could be spared. Other advantages in temocillin use are that it is well-tolerated; it is associated with a low rate of C. difficile infections; it is active against ESBL, AmpC, and KPC-producing Enterobacterales; and it can be used in the OPAT clinical setting.

Keywords